[Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia]

Area of Science:

• Hematology
• Immunology
• Molecular Biology

Context:

• Acute myeloblastic leukemia (AML) is a heterogeneous hematologic malignancy.
• Understanding the molecular markers associated with AML prognosis is crucial for effective treatment strategies.
• Bcl-2 protein plays a significant role in apoptosis and cell survival.

Purpose:

• To investigate the expression levels of Bcl-2 protein in newly diagnosed AML patients.
• To correlate Bcl-2 expression with French-American-British (FAB) subtypes, CD34 expression, and clinical outcomes.
• To identify potential prognostic factors for achieving complete remission (CR) in AML.

Summary:

• Flow cytometry analysis of 67 AML patients revealed heterogeneous Bcl-2 protein expression (mean 81%).
• Higher Bcl-2 expression and Mean Fluorescence Index (MFI) were observed in M0 and M1 FAB subtypes compared to M4 and M5.
• Bcl-2 MFI significantly correlated with CD34 positivity and MFI.
• High Bcl-2 expression (≥20% positive cells) was associated with a lower complete remission rate (40.4%) compared to low expression (<20% positive cells, 72%).

Impact:

• Bcl-2 protein expression and CD34 positivity are identified as independent prognostic factors for achieving complete remission in AML.
• These findings may aid in risk stratification and personalized treatment approaches for AML patients.
• Further research into targeting Bcl-2 pathways could offer new therapeutic avenues for AML.